NS 5806KV4.3 channel activator CAS# 426834-69-7 |
2D Structure
- Melphalan
Catalog No.:BCC2403
CAS No.:148-82-3
- GRI 977143
Catalog No.:BCC2401
CAS No.:325850-81-5
- Mdivi 1
Catalog No.:BCC2402
CAS No.:338967-87-6
- DAPK Substrate Peptide
Catalog No.:BCC2400
CAS No.:386769-53-5
- Cesium chloride
Catalog No.:BCC2399
CAS No.:7647-17-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 426834-69-7 | SDF | Download SDF |
PubChem ID | 11642685 | Appearance | Powder |
Formula | C16H8Br2F6N6O | M.Wt | 574.07 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 50 mM in ethanol | ||
Chemical Name | 1-[3,5-bis(trifluoromethyl)phenyl]-3-[2,4-dibromo-6-(2H-tetrazol-5-yl)phenyl]urea | ||
SMILES | C1=C(C=C(C=C1C(F)(F)F)NC(=O)NC2=C(C=C(C=C2C3=NNN=N3)Br)Br)C(F)(F)F | ||
Standard InChIKey | UZWJWROOLOOCPQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H8Br2F6N6O/c17-8-4-10(13-27-29-30-28-13)12(11(18)5-8)26-14(31)25-9-2-6(15(19,20)21)1-7(3-9)16(22,23)24/h1-5H,(H2,25,26,31)(H,27,28,29,30) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | KV4.3 channel activator; mediates the transient outward K+ current (Ito). Increases IKv4.3 peak current amplitude in CHO-K1 cells expressing KV4.3 and KChIP2 (EC50 = 5.3 μM). Inhibits KV1.4-mediated currents independently of KChIP2. Also slows the decay of KV4.2 and KV4.3 currents in the presence of KChIP2. |
NS 5806 Dilution Calculator
NS 5806 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7419 mL | 8.7097 mL | 17.4195 mL | 34.839 mL | 43.5487 mL |
5 mM | 0.3484 mL | 1.7419 mL | 3.4839 mL | 6.9678 mL | 8.7097 mL |
10 mM | 0.1742 mL | 0.871 mL | 1.7419 mL | 3.4839 mL | 4.3549 mL |
50 mM | 0.0348 mL | 0.1742 mL | 0.3484 mL | 0.6968 mL | 0.871 mL |
100 mM | 0.0174 mL | 0.0871 mL | 0.1742 mL | 0.3484 mL | 0.4355 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 4-Hydroxy-3-methoxyphenyl O-beta-D-6-O-syringate-glucopyranoside
Catalog No.:BCN1442
CAS No.:426821-85-4
- Hemapolin
Catalog No.:BCC8994
CAS No.:4267-80-5
- Dehydrodiconiferyl alcohol
Catalog No.:BCN6878
CAS No.:4263-87-0
- 21,23-Dihydro-23-hydroxy-21-oxozapoterin
Catalog No.:BCN7230
CAS No.:426266-88-8
- TAK-700 salt
Catalog No.:BCC1979
CAS No.:426219-53-6
- TAK-700 (Orteronel)
Catalog No.:BCC2280
CAS No.:426219-18-3
- Luteolin-6-C-glucoside
Catalog No.:BCN4985
CAS No.:4261-42-1
- 8-Hydroxy-5-O-beta-D-glucopyranosylpsoralen
Catalog No.:BCN1443
CAS No.:425680-98-4
- Sotrastaurin (AEB071)
Catalog No.:BCC3857
CAS No.:425637-18-9
- Crocin
Catalog No.:BCN2373
CAS No.:42553-65-1
- Semagacestat (LY450139)
Catalog No.:BCC3610
CAS No.:425386-60-3
- IPA-3
Catalog No.:BCC4978
CAS No.:42521-82-4
- S-Isopropylisothiourea hydrobromide
Catalog No.:BCC6837
CAS No.:4269-97-0
- Cyproterone Acetate
Catalog No.:BCC3758
CAS No.:427-51-0
- Pedunculoside
Catalog No.:BCN1191
CAS No.:42719-32-4
- 2-Aminophenyl phenyl sulfone
Catalog No.:BCC8554
CAS No.:4273-98-7
- D-Valinol
Catalog No.:BCC2693
CAS No.:4276-09-9
- Magnoflorine Iodide
Catalog No.:BCN2911
CAS No.:4277-43-4
- H-N-Me-Leu-OBzl.TosOH
Catalog No.:BCC3215
CAS No.:42807-66-9
- Shinjulactone L
Catalog No.:BCN7958
CAS No.:4283-49-2
- Catechin 7-xyloside
Catalog No.:BCN5484
CAS No.:42830-48-8
- Flumequine
Catalog No.:BCC5090
CAS No.:42835-25-6
- Flumequine sodium
Catalog No.:BCC8985
CAS No.:42835-68-7
- H-Ala-OBzl.TosOH
Catalog No.:BCC3191
CAS No.:42854-62-6
Differential effects of the transient outward K(+) current activator NS5806 in the canine left ventricle.[Pubmed:19632239]
J Mol Cell Cardiol. 2010 Jan;48(1):191-200.
To examine the electrophysiological and molecular properties of the transient outward current (I(to)) in canine left ventricle using a novel I(to) activator, NS5806, I(to) was measured in isolated epicardial (Epi), midmyocardial (Mid) and endocardial (Endo) cells using whole-cell patch-clamp techniques. NS5806 activation of K(v)4.3 current was also studied in CHO-K1 cells and Xenopus laevis oocytes. In CHO-K1 cells co-transfected with K(v)4.3 and KChIP2, NS5806 (10 microM) caused a 35% increase in current amplitude and a marked slowing of current decay with tau increasing from 7.0+/-0.4 to 10.2+/-0.3 ms. In the absence of KChIP2, current decay was unaffected by NS5806. In ventricular myocytes, NS5806 increased I(to) density by 80%, 82%, and 16% in Epi, Mid, and Endo myocytes, respectively (at +40 mV) and shifted steady-state inactivation to negative potentials. NS5806 also significantly slowed decay of I(to), increasing total charge to 227%, 192% and 83% of control in Epi, Mid and Endo cells, respectively (+40 mV, p<0.05). Quantification of K(v)4.3 and KChIP2 mRNA in the 3 ventricular cell types revealed that levels of K(v)4.3 message was uniform but those of KChIP2 were significantly greater in Epi and Mid cells. The KChIP2 gradient was confirmed at the protein level by Western blot. Our results suggest that NS5806 augments I(to) by increasing current density and slowing decay and that both depend on the presence of KChIP2. I(to) and its augmentation by NS5806 are greatest in Epi and Mid cells because KChIP2 levels are highest in these cell types.
Effect of the I(to) activator NS5806 on cloned K(V)4 channels depends on the accessory protein KChIP2.[Pubmed:20649599]
Br J Pharmacol. 2010 Aug;160(8):2028-44.
BACKGROUND AND PURPOSE: The compound NS5806 increases the transient outward current (I(to)) in canine ventricular cardiomyocytes and slows current decay. In human and canine ventricle, I(to) is thought to be mediated by K(V)4.3 and various ancillary proteins, yet, the exact subunit composition of I(to) channels is still debated. Here we characterize the effect of NS5806 on heterologously expressed putative I(to) channel subunits and other potassium channels. EXPERIMENTAL APPROACH: Cloned K(V)4 channels were co-expressed with KChIP2, DPP6, DPP10, KCNE2, KCNE3 and K(V)1.4 in Xenopus laevis oocytes or CHO-K1 cells. KEY RESULTS: NS5806 increased K(V)4.3/KChIP2 peak current amplitudes with an EC(50) of 5.3 +/- 1.5microM and significantly slowed current decay. KCNE2, KCNE3, DPP6 and DPP10 modulated K(V)4.3 currents and the response to NS5806, but current decay was slowed only in complexes containing KChIP2. The effect of NS5806 on K(V)4.2 was similar to that on K(V)4.3, and current decay was only slowed in presence of KChIP2. However, for K(V)4.1, the slowing of current decay by NS5806 was independent of KChIP2. K(V)1.4 was strongly inhibited by 10 microM NS5806 and K(V)1.5 was inhibited to a smaller extent. Effects of NS5806 on kinetics of currents generated by K(V)4.3/KChIP2/DPP6 with K(V)1.4 in oocytes could reproduce those on cardiac I(to) in canine ventricular myocytes. K(V)7.1, K(V)11.1 and K(ir)2 currents were unaffected by NS5806. CONCLUSION AND IMPLICATIONS: NS5806 modulated K(V)4 channel gating depending on the presence of KChIP2, suggesting that NS5806 can potentially be used to address the molecular composition as well as the physiological role of cardiac I(to).
A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome.[Pubmed:19073629]
Cardiovasc Res. 2009 Mar 1;81(4):686-94.
AIMS: Transient outward potassium current (I(to)) is thought to be central to the pathogenesis of the Brugada syndrome (BrS). However, an I((to)) activator has not been available with which to validate this hypothesis. Here, we provide a direct test of the hypothesis using a novel I(to) activator, NS5806. METHODS AND RESULTS: Isolated canine ventricular myocytes and coronary-perfused wedge preparations were used. Whole-cell patch-clamp studies showed that NS5806 (10 microM) increased peak I(to) at +40 mV by 79 +/- 4% (24.5 +/- 2.2 to 43.6 +/- 3.4 pA/pF, n = 7) and slowed the time constant of inactivation from 12.6 +/- 3.2 to 20.3 +/- 2.9 ms (n = 7). The total charge carried by I(to) increased by 186% (from 363.9 +/- 40.0 to 1042.0 +/- 103.5 pA x ms/pF, n = 7). In ventricular wedge preparations, NS5806 increased phase 1 and notch amplitude of the action potential in the epicardium, but not in the endocardium, and accentuated the ECG J-wave, leading to the development of phase 2 re-entry and polymorphic ventricular tachycardia (n = 9). Although sodium and calcium channel blockers are capable of inducing BrS only in right ventricular (RV) wedge preparations, the I(to) activator was able to induce the phenotype in wedges from both ventricles. NS5806 induced BrS in 4/6 right and 2/10 left ventricular wedge preparations. CONCLUSION: The I(to) activator NS5806 recapitulates the electrographic and arrhythmic manifestation of BrS, providing evidence in support of its pivotal role in the genesis of the disease. Our findings also suggest that a genetic defect leading to a gain of function of I(to) could explain variants of BrS, in which ST-segment elevation or J-waves are evident in both right and left ECG leads.